Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 6/20 | 0.38 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.37 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.37 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.37 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1019141 | 0.89 | ACKR3 (0.43) | CHRM4ACKR3MAOB | |
| SCHEMBL1018759 | 0.89 | MEN1 (0.42) | — | |
| SCHEMBL1019162 | 0.87 | MEN1 (0.44) | ACKR3 | |
| SCHEMBL1019812 | 0.86 | PRKAB2 (0.47) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1019054 | 0.85 | HTT (0.44) | TP53MAPT | |
| Hydrochloric Acid SCHEMBL3690436 | 0.85 | HTT (0.43) | TP53MAPT | |
| SCHEMBL1020415 | 0.83 | HTT (0.46) | ACKR3TP53MAPT | |
| SCHEMBL12954825 | 0.83 | MEN1 (0.46) | ACKR3PRKAB2PRKAG1PRKAA2PRKAA1 | |
| Trifluoroacetic Acid SCHEMBL1018638 | 0.82 | PRKAB2 (0.48) | ACKR3PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1018897 | 0.81 | MEN1 (0.41) | ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | claimed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | NPC1L1, NPC1, ABCB11 | CHRM4 4182/4885ACKR3 1939/4885PRKAB2 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.